# VC_PE Funds Portfolio Analysis.docx

# Strategic Capital Deployment in the Global Animal Health and Agrifood Ecosystems: An Exhaustive Analysis of Private Equity and Venture Capital Portfolios

## 1. Executive Introduction

The convergence of animal health, veterinary medicine, and advanced agrifood systems represents one of the most dynamic frontiers in global capital allocation. Over the past decade, the investment thesis for these sectors has evolved from niche plays into central pillars of value creation for some of the world's largest asset managers. This transformation is driven by three powerful secular trends: the "humanization" of companion animals, which necessitates human-grade healthcare and nutrition; the imperative for sustainable protein production to feed a growing global population; and the digitization of biological workflows.

This report provides a comprehensive, expert-level analysis of a specific cohort of Venture Capital (VC) and Private Equity (PE) funds that are actively shaping this landscape. The funds analyzed range from specialized, early-stage investors like Digitalis Ventures and Ani.VC—who fund high-risk, high-reward deep science—to massive global buyout firms like EQT and Morgan Stanley Capital Partners, who are consolidating fragmented service markets and verticalizing entire industries.

Collectively, the funds analyzed herein manage hundreds of billions of dollars in assets, with specific multi-billion dollar allocations directed toward the companies detailed in this report. By dissecting the portfolios of these firms, we observe a clear bifurcation in strategy: VCs are funding the "software" of biology (genomics, microbiome, precision fermentation), while PEs are optimizing the "hardware" (clinics, hospitals, manufacturing, and logistics).

The following sections detail the Assets Under Management (AUM), investment philosophies, and granular portfolio compositions for each fund. Per the research mandate, every identified portfolio company is classified by sector (Veterinary vs. Other) and analyzed for its specific involvement in Pet Food and Nutraceuticals.

## 2. Digitalis Ventures

### 2.1. Fund Overview and Assets Under Management (AUM)

Digitalis Ventures is a venture capital firm headquartered in New York City that operates at the intersection of math, physics, computing, chemistry, and biology. The firm manages approximately $925 million in assets under management (AUM).1 Digitalis is unique in its structural approach to the animal health market; it manages the Companion Fund, a corporate venture capital arrangement backed by Mars Petcare.

This partnership allows Digitalis to deploy capital with the financial discipline of a traditional VC while offering portfolio companies access to the immense operational resources, distribution networks, and R&D capabilities of Mars, one of the world's largest pet care entities. The firm recently launched Companion Fund II, a $300 million vehicle designed to back founders leveraging breakthrough science to improve the lives of pets, pet owners, and veterinarians.2 This follows the success of the initial $100 million fund, signaling a quadrupling of their commitment to the sector.3

### 2.2. Portfolio Architecture and Analysis

The Digitalis portfolio is characterized by "deep science." Unlike consumer-only funds, Digitalis invests heavily in therapeutics, diagnostics, and advanced computation. Their portfolio reflects a conviction that veterinary medicine is ready for the same biotechnological revolution that has transformed human healthcare.

#### Table 1: Digitalis Ventures Portfolio Analysis

## 3. Ani.VC

### 3.1. Fund Overview and Assets Under Management (AUM)

Ani.VC is a specialist venture capital firm launched in 2024 to capitalize on the booming "Pet Economy." Based in Miami and New York, the firm operates as an independent fund focused on early-stage opportunities across the US, Europe, and Asia.

AUM: The fund has announced a capital deployment target of $35 million over its first three years.4

Investment Thesis: Ani.VC explicitly targets the "Pet Longevity" and "Pet Lifestyle" verticals. The firm identifies a gap in funding for startups that are too early for massive PE firms but require sector-specific expertise that generalist VCs lack. Their focus spans veterinary health, therapeutics, diagnostics, and modern consumer services.

### 3.2. Portfolio Architecture and Analysis

Despite being a new entrant, Ani.VC has quickly assembled a portfolio that targets high-value niches: longevity therapeutics and premium social experiences.

#### Table 2: Ani.VC Portfolio Analysis

## 4. Stray Dog Capital

### 4.1. Fund Overview and Assets Under Management (AUM)

Stray Dog Capital is a mission-driven venture capital firm that invests in the future of food. While their primary lens is the removal of animals from the human food supply chain, this thesis has naturally extended into the pet food sector, which consumes approximately 25% of all meat in the US.

AUM: Approximately $90 million across multiple funds.5

Investment Thesis: Stray Dog invests in early-stage companies driving the transition to a more sustainable, humane, and healthy food system. Key pillars include plant-based proteins, precision fermentation, and cellular agriculture.

### 4.2. Portfolio Architecture and Analysis

Stray Dog’s portfolio is a masterclass in alternative proteins. The implications for the pet industry are profound: as human consumers shift away from factory-farmed meat, they increasingly demand the same ethical standards for their pets.

#### Table 3: Stray Dog Capital Portfolio Analysis (Select Relevant Investments)

## 5. Borealis Ventures

### 5.1. Fund Overview and Assets Under Management (AUM)

Borealis Ventures is an early-stage venture firm based in Hanover, NH. Their investment strategy is bifurcated into healthcare and the built environment. Within healthcare, they have a dedicated focus on life sciences and digital health, with a specific sub-thesis on veterinary technology.

AUM: Less than $150 million.6

Investment Thesis: Borealis seeks to partner with entrepreneurs driving "paradigm shifts" in healthcare. In the veterinary space, this translates to investments in data, genomics, and marketplace efficiency.

### 5.2. Portfolio Architecture and Analysis

Borealis does not focus on pet food; instead, they invest in the infrastructure and data layers of veterinary medicine.

#### Table 4: Borealis Ventures Portfolio Analysis

## 6. S2G Investments (Seed to Growth)

### 6.1. Fund Overview and Assets Under Management (AUM)

S2G Investments is a multi-stage investment firm focused on the entire food and agriculture spectrum, from "Soil to Shelf," as well as oceans and clean energy.

AUM: Approximately $2.5 Billion.7

Investment Thesis: S2G invests in companies that can generate competitive financial returns while producing positive social and environmental impacts. Their scope includes agriculture, ingredients, branded food, and supply chain technology.

### 6.2. Portfolio Architecture and Analysis

S2G's portfolio is massive. For the purpose of this report, we focus on companies relevant to animal nutrition, ag-tech inputs for feed, and sustainable protein.

#### Table 5: S2G Investments Portfolio Analysis (Relevant Selections)

## 7. Tyson Ventures

### 7.1. Fund Overview and Assets Under Management (AUM)

Tyson Ventures is the corporate venture capital arm of Tyson Foods, one of the world's largest meat producers.

AUM: The fund invests off the corporate balance sheet. They allocated an initial $100 million for investment, but total deployment is flexible based on strategic fit.8

Investment Thesis: Tyson Ventures acts as a strategic hedge. Recognizing the environmental limits of traditional meat production, they invest aggressively in "Alternative Proteins" (insects, cell-cultured, plant-based) and "Emerging Technologies" that improve supply chain efficiency.

### 7.2. Portfolio Architecture and Analysis

Tyson’s portfolio reveals a company pivoting from "Meat Producer" to "Protein Provider."

#### Table 6: Tyson Ventures Portfolio Analysis

## 8. Seventure Partners (AVF & Health for Life)

### 8.1. Fund Overview and Assets Under Management (AUM)

Seventure Partners is a leading French venture capital firm and a subsidiary of Natixis Investment Managers. They are globally renowned for their leadership in microbiome investing.

AUM: Total AUM is approximately €950 million to €1 billion.9

Specific Funds:

Health for Life Capital™: ~€160M+ vehicle focused on the microbiome in health and nutrition.

AVF (Animal Health, Feed, and Nutrition): A €24 million dedicated fund targeting animal health and livestock technologies.10

### 8.2. Portfolio Architecture and Analysis

Seventure’s portfolio is the "Gold Standard" for microbiome science. They understand that the gut is the center of health for both humans and animals.

#### Table 7: Seventure Partners Portfolio Analysis

## 9. Gryphon Investors

### 9.1. Fund Overview and Assets Under Management (AUM)

Gryphon Investors is a middle-market private equity firm based in San Francisco. The firm manages approximately $9 billion in assets.11 Gryphon’s strategy revolves around building "market leaders" through proactive sector initiatives in Business Services, Consumer, Healthcare, and Industrial Growth.

### 9.2. Portfolio Architecture and Analysis

Gryphon has aggressively targeted the Pet Health and Veterinary Services sectors, executing a classic "Buy and Build" strategy to consolidate fragmented markets.

#### Table 8: Gryphon Investors Portfolio Analysis

## 10. Morgan Stanley Capital Partners (MSCP)

### 10.1. Fund Overview and Assets Under Management (AUM)

Morgan Stanley Capital Partners (MSCP) is the middle-market private equity team within Morgan Stanley Investment Management (MSIM), which holds over $1.5 trillion in total AUM. MSCP specializes in operationally-focused buyouts in the Consumer and Healthcare sectors.

### 10.2. Portfolio Architecture and Analysis

MSCP acts as a "kingmaker" in the pet industry, having successfully built and sold some of the sector's most prominent platforms.

#### Table 9: Morgan Stanley Capital Partners Portfolio Analysis

## 11. EQT Group

### 11.1. Fund Overview and Assets Under Management (AUM)

EQT is a global purpose-driven investment organization based in Sweden. With a total gross AUM of approximately €246 billion 12, EQT is one of the most active private equity investors in the European animal health landscape.

### 11.2. Portfolio Architecture and Analysis

EQT has constructed a vertically integrated "Pet Ecosystem," owning assets across the entire value chain: the clinic, the pharmacy, the retailer, and the insurer.

#### Table 10: EQT Group Portfolio Analysis

## 12. Aqua-Spark

### 12.1. Fund Overview and Assets Under Management (AUM)

Aqua-Spark is a Dutch investment fund exclusively dedicated to sustainable aquaculture. Managing approximately $500 million in assets 13, the fund invests in the entire aquaculture value chain—from feed ingredients to farming operations and technology.

### 12.2. Portfolio Architecture and Analysis

Aqua-Spark is a critical upstream enabler for the pet food industry. As pet food brands seek sustainable protein sources to lower their carbon footprint, Aqua-Spark's portfolio companies provide the solution.

#### Table 11: Aqua-Spark Portfolio Analysis

## 13. WP Global Partners

### 13.1. Fund Overview and Assets Under Management (AUM)

WP Global Partners is a private markets firm focused on small to middle-market buyouts, debt, and venture. The firm manages approximately $4-5 billion in total assets.

### 13.2. Portfolio Analysis

WP Global invests in platforms that can be scaled through de novo growth and operational improvements.

#### Table 12: WP Global Partners Portfolio Analysis

## 14. Inflexion

### 14.1. Fund Overview and Assets Under Management (AUM)

Inflexion is a UK mid-market private equity firm investing in high-growth businesses. They manage approximately £10 billion in assets.14

### 14.2. Portfolio Analysis

Inflexion has a proven track record of internationalizing UK-based animal health businesses.

#### Table 13: Inflexion Portfolio Analysis

## 15. NovaQuest Capital Management

### 15.1. Fund Overview and Assets Under Management (AUM)

NovaQuest specializes in product finance and equity investments in biopharma and animal health. With over $2.5 billion in AUM 15, they use a unique "Product Finance" model to fund specific late-stage clinical assets rather than just company equity.

### 15.2. Portfolio Analysis

NovaQuest’s portfolio targets high-value therapeutic assets.

#### Table 14: NovaQuest Portfolio Analysis

## 16. Ocean 14 Capital

### 16.1. Fund Overview and Assets Under Management (AUM)

Ocean 14 Capital is a private equity impact fund focused on the United Nations' Sustainable Development Goal 14 (Life Below Water). The fund targets a size of €200 million.16

### 16.2. Portfolio Analysis

Ocean 14 invests in technologies that regenerate ocean health, often overlapping with the sustainable seafood supply chain.

#### Table 15: Ocean 14 Capital Portfolio Analysis

## 17. Additional Funds (Summarized)

### 17.1. Fulcrum Global Capital (FGC)

Focus: Agriculture and Animal Health.

Portfolio: P&P Optica (meat inspection), Green Dot Bioplastics, NanoGuard (food safety), Resilient Biotics (microbiome therapeutics for respiratory disease in livestock), Vytelle (cattle genetics/IVF).

### 17.2. Cavallo Ventures (Wilbur-Ellis)

Focus: AgTech and Ingredients.

Portfolio: Bond Pet Foods (fermentation protein), Omeat (cultivated meat), Vestaron (peptide-based crop protection), Native Microbials (microbiome for livestock), Soma Detect (milk sensors).

### 17.3. Anterra Capital

Focus: Food and AgTech.

Portfolio: BiomEdit (animal microbiome innovation), Enko (crop protection), Invetx (veterinary monoclonal antibodies - exited), Animol (small molecule vet drugs).

### 17.4. Nutreco (NuFrontiers)

Focus: Animal Nutrition and Aquafeed.

Portfolio: BlueNalu (cellular seafood), Mosa Meat (cultured beef), Proteon (phages), ViAqua (RNA particles for shrimp health), Eruvaka (shrimp farming IoT).

### 17.5. Blue Horizon

Focus: Alternative Proteins (Food System).

Portfolio: Beyond Meat, Mosa Meat, Wild Earth (vegan dog food), The EVERY Company (animal-free egg protein), Geltor (collagen).

### 17.6. Cibus Fund

Focus: Mid-market AgTech and Food.

Portfolio: 4AG Robotics (mushroom harvesting), Growers Edge (fintech for farmers), The Kingfish Company (aquaculture), Ecorobotix (precision spraying).

### 17.7. Vestar Capital Partners

Focus: Consumer and Healthcare.

Portfolio: PetHonesty (natural pet supplements), Big Heart Pet Brands (exited - major pet food portfolio including Milk-Bone, Meow Mix).

## 18. Conclusion

The capital allocation strategies detailed above reveal a synchronized effort to reshape the biological and industrial realities of the pet and food industries.

Vertical Integration: Firms like EQT and Gryphon are not merely buying assets; they are constructing vertically integrated platforms. By controlling the veterinary clinic (IVC, Heartland), the pharmacy (Dechra, Vetnique), and the retail channel (Zooplus), they capture value at every step of the pet owner's journey.

The "Humanization" of Science: Investment in companies like Gallant, Fidocure, and BiomEdit confirms that the "humanization" trend has graduated from premium kibble to human-grade medicine. Pets are now the recipients of stem cell therapies, monoclonal antibodies, and precision oncology treatments previously reserved for humans.

Sustainability as Supply Chain: The portfolios of Aqua-Spark, S2G, and Stray Dog highlight that the future of pet food is animal-free. Whether through insect protein (Protix) or precision fermentation (Bond Pet Foods), the industry is actively decoupling pet nutrition from traditional slaughter-based agriculture to meet sustainability goals.

#### Works cited

Digitalis Ventures - Capital AUM - Private Equity, accessed on January 9, 2026, https://capitalaum.com/venture-capital/digitalisventures-newyork-ny.htm

Mars and Digitalis Ventures launch $300m Fund to improve the lives of pets, accessed on January 9, 2026, https://www.mars.com/news-and-stories/press-releases-statements/mars-and-digitalis-ventures-launch-300m-dollar-companion-fund-ii

Mars Companion Fund to take bigger bets on petcare startups - - Global Corporate Venturing, accessed on January 9, 2026, https://globalventuring.com/corporate/consumer/mars-companion-fund-interview/

Ani.VC launches a fund for pets and first investment in DOG PPL, accessed on January 9, 2026, https://ani.vc/media/anivc-launches-a-fund-for-pets-and-first-investment-in-dog-ppl

Meet Lisa Feria, Managing Partner and CEO at Stray Dog Capital - VatorNews, accessed on January 9, 2026, https://vator.tv/2022-12-01-meet-lisa-feria-managing-partner-and-ceo-at-stray-dog-capital/

Borealis Ventures - Fund and Executive Details, accessed on January 9, 2026, https://privatefunddata.com/fund-companies/borealis-ventures/

Impact 50: S2G mines 'seams' of sectors in impact investing - New Private Markets, accessed on January 9, 2026, https://www.newprivatemarkets.com/impact-50-s2g-mines-seams-of-sectors-in-impact-investing/

Tyson Foods invests in Protix; Veolia Malaysia gets EU insect meal export approval, accessed on January 9, 2026, https://www.seafoodsource.com/news/supply-trade/tyson-foods-invests-in-protix-veolia-malaysia-gets-eu-insect-meal-export-approval

About Seventure, accessed on January 9, 2026, https://www.seventure.fr/en/about/about-seventure/

Our Institutional Funds | Seventure, accessed on January 9, 2026, https://www.seventure.fr/en/products/our-institutional-funds/

Gryphon Investors Named to Inc.'s 2023 List of Founder-Friendly Investors, accessed on January 9, 2026, https://www.gryphon-inv.com/news/gryphon-investors-named-to-inc-s-2023-list-of-founder-friendly-investors/

EQT to acquire VetPartners, the leading provider of veterinary and animal health services in Australia and New Zealand, accessed on January 9, 2026, https://eqtgroup.com/news/eqt-to-acquire-vetpartners-the-leading-provider-of-veterinary-and-animal-health-services-in-australia-and-new-zealand-2023-10-11

Aqua-Spark - ImpactAssets 50, accessed on January 9, 2026, https://impactassets.org/ia50/fund.php?id=a012R00001KeC47QAF

Inflexion marks 25 years of backing ambition, accessed on January 9, 2026, https://www.inflexion.com/news-and-insights/news/2024/inflexion-marks-25-years-of-backing-ambition/

About NovaQuest, accessed on January 9, 2026, https://www.novaquest.com/about/

Ocean 14 Capital Fund I reaches hard cap of €200 million providing transformative investment into the global 'Blue Economy', accessed on January 9, 2026, https://ocean14capital.com/2024/05/10/ocean-14-capital-fund-i-reaches-hard-cap-of-e200-million-providing-transformative-investment-into-the-global-blue-economy/